PDX is a novel, small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, or DHFR, a folic acid (folate)-dependent enzyme involved in the building of nucleic acid, or DNA, and otherprocesses.
PDX was rationally designed for efficient transport into tumor cells via the reduced folate carrier, or RFC-1, and effective intracellular drug retention.
PDX has been awarded the USFDA orphan drug designation in July 2006 for the treatment of patients with T-cell lymphoma and in October 2006 has been granted FDA fast track designation for the treatment of patients with T-cell lymphoma.
Accounting for approximately 10% to 15% of all cases of non-Hodgkin's lymphoma (NHL), peripheral T-cell lymphomas (or PTCLs) are a biologically diverse group of blood cancers with an average five year survival rate of approximately 25%.
Currently, there are no pharmaceutical agents approved for the treatment of either first-line or relapsed or refractory PTCLs.
Find more details from the full report.
Comment Preview